Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infection: early-phase trial registry
9 of 74 indexed HIV Infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #183 of 28,707 conditions by registered trial count.
74 US clinical trials · 9 currently recruiting · #183 of 28,707 conditions by registered trial count
HIV Infection: 74 US clinical trials tracked, 9 recruiting.
HIV Infection is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 12 of these trials.
Enrollment posture brief
Registry condition hiv-infection
OPEN 9 | RECR 12% | LATE 15 | EARLY 32 | RANK #183 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Hepatitis C (12% recruiting · 108 trials)
HIV Infection lists 9 open slots (12% of 74 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infection is recruiting below its size-band peers.
9 of 74 indexed trials (12.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infection research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 12 of 74 trials (16.2%). 40 distinct sponsors appear on at least one study for this condition label.
-
Most HIV Infection trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 74 trials that report a genuine target (sentinel values excluded). 48 of those (64.9%) plan for fewer than 100 participants.
-
HIV Infection research is mostly interventional.
57 interventional and 17 observational studies make up this index (77% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
74 total, page 1 of 2
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02140255
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Washington University School of Medicine
NCT05965245
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium
NCT05663502
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
AIDS Malignancy Consortium
NCT04949464
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
University of Texas Southwestern Medical Center
NCT06659952
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
NCT04929028
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
NCT05077527
MAPS PrEP Van Study
Duke University
NCT06908252
The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection
Icahn School of Medicine at Mount Sinai
NCT05652088
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Merck Sharp & Dohme
NCT05766501
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
Jonsson Comprehensive Cancer Center
NCT02816879
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04340596
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Gilead Sciences
NCT05729568
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
AIDS Malignancy Consortium
NCT02437851
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
AIDS Malignancy Consortium
NCT02797470
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT02337985
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT01961063
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
AIDS Malignancy Consortium
NCT02135419
Comparative Study of Three NNRTI-Sparing HAART Regimens
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT00811954
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NCT00955968
Study of Patients With Strongyloides Stercoralis Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001245
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
Merck Sharp & Dohme
NCT04223791
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04193189
Development of Serologic Assays for Human Herpes Virus-8
National Institutes of Health Clinical Center (CC)
NCT00395278
Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
University of North Carolina, Chapel Hill
NCT01629316
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
GlaxoSmithKline
NCT00053638
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
University of North Carolina, Chapel Hill
NCT00142740
Safety and Efficacy Study of Switching From Epzicom to Truvada
Gilead Sciences
NCT00724711
Effects of HIV on the Development and Function of Bone Marrow Cells
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001243
HLA-B*5701 And Hypersensitivity To Abacavir
GlaxoSmithKline
NCT00373945
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
University of Pennsylvania
NCT01262846
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
National Institute on Drug Abuse (NIDA)
NCT00870792
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
Abbott
NCT00234910
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
University of North Carolina, Chapel Hill
NCT00107029
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
National Institute of Dental and Craniofacial Research (NIDCR)
NCT00001524
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
Johns Hopkins University
NCT02602262
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
University of North Carolina, Chapel Hill
NCT00710593
Capravirine to Treat Children With HIV Infection
National Cancer Institute (NCI)
NCT00006519
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
AIDS Malignancy Consortium
NCT01946217
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001357
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
ViiV Healthcare
NCT00040664
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
University of California, San Diego
NCT00281606
Study on Immunopathogenesis in HIV and Hepatitis C Coinfection
Rush University Medical Center
NCT01296529
The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00724178
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
GlaxoSmithKline
NCT00386347
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
Montefiore Medical Center
NCT00785616
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
National Cancer Institute (NCI)
NCT00001826
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
Northwestern University
NCT00225017
Twins Study of Gene Therapy for HIV Infection
National Human Genome Research Institute (NHGRI)
NCT00001535
Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
International AIDS Vaccine Initiative
NCT00252148
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 12 |
| Phase 3 | 8 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infection page
74 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 HIV Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infection trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infection condition card totals 74 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.